Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8808 versus MabThera plus CHOP in advanced CD20-positive follicular lymphoma
2012-004190-12Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing MK-8808 plus CHOP with MabThera plus CHOP (2 arms). Primary endpoint: CR+CRu rate. Started Jan 2013; status: terminated.
02
Drugs
MabionCD20rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2012-004190-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004190-12.